Next Article in Journal
Clinical Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation
Next Article in Special Issue
Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
Previous Article in Journal
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma
Previous Article in Special Issue
Hyperprogression under Immunotherapy
Open AccessArticle

High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations

Institute of Hematology and Blood Transfusion, Prague 128 20, Czech Republic
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(11), 2823; https://doi.org/10.3390/ijms20112823
Received: 30 April 2019 / Revised: 31 May 2019 / Accepted: 6 June 2019 / Published: 10 June 2019
(This article belongs to the Special Issue PD-L1, A Master Regulator of Immunity)
Compared to solid tumors, the role of PD-L1 in hematological malignancies is less explored, and the knowledge in this area is mostly limited to lymphomas. However, several studies indicated that PD-L1 is also overexpressed in myeloid malignancies. Successful treatment of the acute myeloid leukemia (AML) is likely associated with elimination of the residual disease by the immune system, and possible involvement of PD-L1 in this process remains to be elucidated. We analyzed PD-L1 expression on AML primary cells by flow cytometry and, in parallel, transcript levels were determined for the transcription variants v1 and v2. The ratio of v1/v2 cDNA correlated with the surface protein amount, and high v1/v2 levels were associated with worse overall survival (p = 0.0045). The prognostic impact of PD-L1 was limited to AML with mutated nucleophosmin and concomitant internal tandem duplications in the FLT3 gene (p less than 0.0001 for this particular AML subgroup). View Full-Text
Keywords: leukemia; AML; FLT3-ITD; NPM1; PD-L1 transcript; PD-1; CD34 leukemia; AML; FLT3-ITD; NPM1; PD-L1 transcript; PD-1; CD34
Show Figures

Graphical abstract

MDPI and ACS Style

Brodská, B.; Otevřelová, P.; Šálek, C.; Fuchs, O.; Gašová, Z.; Kuželová, K. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. Int. J. Mol. Sci. 2019, 20, 2823.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop